Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies

NCT02904226 is registered in ClinicalTrials.gov with Jounce Therapeutics, Inc. as lead sponsor.

NCT NCT02904226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02904226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies
Lead sponsor
Jounce Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2016
Completion date
July 1, 2020
Enrollment
242 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cancer